Last reviewed · How we verify
Desirudin or Argatroban® — Competitive Intelligence Brief
marketed
Small molecule
Live · refreshed every 30 min
Target snapshot
Desirudin or Argatroban® (Desirudin or Argatroban®) — Canyon Pharmaceuticals, Inc..
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Desirudin or Argatroban® TARGET | Desirudin or Argatroban® | Canyon Pharmaceuticals, Inc. | marketed |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Desirudin or Argatroban® CI watch — RSS
- Desirudin or Argatroban® CI watch — Atom
- Desirudin or Argatroban® CI watch — JSON
- Desirudin or Argatroban® alone — RSS
Cite this brief
Drug Landscape (2026). Desirudin or Argatroban® — Competitive Intelligence Brief. https://druglandscape.com/ci/desirudin-or-argatroban. Accessed 2026-05-16.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab